Hypertension, Vol 7, 178-181, Copyright © 1985 by American Heart Association
GT Griffing, TE Wilson and JC Melby
19-Nor-deoxycorticosterone (19-nor-DOC) is a human mineralocorticoid. The
regulation of its secretion is poorly understood, as renin angiotensin II
(ANG II) stimulation has minimal effects on 19-nor-DOC. This study sought
to determine if ANG II inhibition would decrease 19- nor-DOC production.
Six normal subjects on fixed electrolyte intake were admitted to a
metabolic unit. After a 5-day control period to establish electrolyte
balance, enalapril, p.o., 10 mg/day, was administered for 28 days. This
treatment resulted in ANG II inhibition, which was reflected by a rise in
plasma renin activity, a blunting of the postural plasma aldosterone
increment, and a decrease in aldosterone secretion rate (ASR). Levels of
urinary free (UF) 19-nor- DOC progressively decreased from 294 +/- 108
ng/day on Day 0 to 164 +/- 70 on Day 3, 141 +/- 62 on Day 7, 101 +/- 38 on
Day 14, 68 +/- 18 on Day 21, and 106 +/- 31 on Day 28. The decrease in
19-nor-DOC levels was synchronous with the fall in ASR (R = 0.94, n = 5, p
less than 0.005), but it was of greater magnitude (71% decrease in
19-nor-DOC levels versus 41% decrease in ASR). In addition, the decrease in
19-nor-DOC levels correlated with a fall in urinary potassium and an
increase in both urinary sodium and chloride (R = 0.68, -0.79, -0.87
respectively; n = 6, p less than 0.05). The fall in ASR, on the other hand,
was not significantly correlated with the changes in these urinary
electrolyte levels (R = 0.65, 0.64, 0.57 respectively; n = 5).(ABSTRACT
TRUNCATED AT 250 WORDS)
ARTICLES
Converting-enzyme inhibitor administration lowers urinary free 19-nor- deoxycorticosterone levels
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |